Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Urinary Bladder Neoplasms: early-phase trial registry
6 of 20 indexed Urinary Bladder Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 6 currently recruiting · #848 of 28,707 conditions by registered trial count
Urinary Bladder Neoplasms: 20 US clinical trials tracked, 6 recruiting.
Urinary Bladder Neoplasms is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 5 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 4 of these trials.
Enrollment posture brief
Registry condition urinary-bladder-neoplasms
OPEN 6 | RECR 30% | LATE 5 | EARLY 15 | RANK #848 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Adrenocortical Carcinoma (30% recruiting · 10 trials)
Urinary Bladder Neoplasms lists 6 open slots (30% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Urinary Bladder Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Urinary Bladder Neoplasms is recruiting below its size-band peers.
6 of 20 indexed trials (30%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Urinary Bladder Neoplasms research.
Janssen Research & Development accounts for 4 of 20 trials (20%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Urinary Bladder Neoplasms enrolment sits around 220 participants.
Median target enrolment is 220 among the 20 trials that report a genuine target (sentinel values excluded). 6 of those (30%) plan for fewer than 100 participants.
-
Urinary Bladder Neoplasms research is mostly interventional.
20 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT04389632
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Eli Lilly and Company
NCT05614739
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Eli Lilly and Company
NCT07218380
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Merck Sharp & Dohme
NCT06833073
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Merck Sharp & Dohme
NCT07222488
Virtual Histology of the Bladder Wall for Bladder Cancer Staging
Jodi Maranchie
NCT04369560
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb
NCT03661320
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Merck Sharp & Dohme
NCT04241185
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Janssen Research & Development
NCT04658862
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Astellas Pharma Global Development
NCT03288545
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
Janssen Research & Development
NCT04640623
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Janssen Research & Development
NCT04919512
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
AstraZeneca
NCT03459846
Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer
Sanofi
NCT00625664
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Astellas Pharma
NCT03219333
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development
NCT04172675
Cabozantinib for Advanced Urothelial Cancer
National Cancer Institute (NCI)
NCT01688999
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
Seth Lerner
NCT00710970
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology
NCT03081858
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
NCT02788201
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 9 |
| Phase 3 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Urinary Bladder Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Urinary Bladder Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Urinary Bladder Neoplasms page
20 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Urinary Bladder Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Urinary Bladder Neoplasms trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Urinary Bladder Neoplasms condition card totals 20 registered trials; most-linked intervention Cetrelimab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.